首页 | 本学科首页   官方微博 | 高级检索  
     


Daclatasvir/peginterferon lambda‐1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa‐2a/ribavirin
Authors:E. Santagostino  S. Pol  A. Olveira  H. W. Reesink  K. van Erpecum  P. Bogomolov  D. Xu  L. Critelli  S. Srinivasan  E. Cooney
Affiliation:1. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Ca' Granda Foundation, Maggiore Hospital Policlinico, Milan, Italy;2. H?pital Cochin, Université Paris Descartes, Inserm U‐818, Institut Pasteur, Paris, France;3. Hospital Universitario La Paz, Madrid, Spain;4. Academic Medical Center, Amsterdam, the Netherlands;5. Universitair Medisch Centrum Utrecht, Utrecht, the Netherlands;6. Clinical Hospital of Tsentrosoyuz, Moscow, Russia;7. Bristol‐Myers Squibb, Inc., Wallingford, CT, USA
Abstract:
Keywords:daclatasvir  haemophilia  hepatitis C  peginterferon lambda‐1a  ribavirin  sustained virologic response
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号